include an indeterminate number of additional shares of common stock as may from time
Series B Preferred, with a stated value of $1,000 and convertible into shares of our common stock at the public offering price
12, 2017, the last reported sale price for our common stock on NASDAQ was $0.39 per share.
offering price per Class A Unit will be determined between us and the underwriter based on the closing price of our common stock
aggregate total of 7,692,308 shares of Common Stock and the Warrants included in the Class B Units will be exercisable for an
have elected to comply with certain reduced public company reporting requirements for future filings.Investing
included as part of the Class B Units sold in this offering) and warrants to purchase a maximum of 2,307,692 shares of common
exercise price equal to 125% of the public offering price of the Class A Units per share of common stock.
of our Series B Preferred, with a stated value of $1,000 and convertible into shares of our common stock, at the public offering
estimate that the net proceeds from our sale of shares of our common stock in this offering will be approximately $5.4 million,
the warrants).•The number of shares of our common stock outstanding after this offering will fluctuate depending on how many Class B Units
expected for the fiscal year 2017.Summary of Statement of Operations DataNine Months EndedSeptember 30,Fiscal Year EndedDecember 31,2017201620162015Total revenue$2,540,942$2,307,708$2,960,912$2,115,050Cost of sales$846,487$713,576$1,083,087$950,792Gross profit$1,694,455$1,594,132$1,877,825$1,164,258Net loss$(3,193,571)$(2,207,707)$(3,303,538)$(9,311,913)Basic and diluted net loss per share$(0.39)$(.41)$(.61)$(1.81)Weighted average basic and diluted shares
approximately 75% of the Company’s product revenue.Because of our dependence on a limited number of key customers, the
adversely affect the Company’s business.We may require additional capital in the future to develop new
we will continue to incur, substantial expense for, and devote a significant amount of time to, product development, pilot trial
may be unable to develop marketable products.Modifications to our devices may require additional FDA approval
market our products and revenue may decline.Our future performance will depend largely on the success of
a material adverse impact on our results of operations.Demands of third-party payors, cost reduction pressures among our
financial position, cash flows and results of operations.Failure to obtain medical reimbursement for our products under
stock price.The preparation of financial statements in conformity with U.S. GAAP requires our management to make estimates, assumptions and
accounts, stock-based compensation expense and income taxes.As an emerging growth company within the meaning of the Securities
requirement, we would expect our common stock to be traded in the over-the-counter market, which could adversely affect the liquidity
business, operating results and financial condition.26The Series B Preferred Stock will be an unlisted security and as
to receive dividends, but rather merely represent the right to acquire shares of common stock at a fixed price for a limited period
by our stockholders of a substantial number of shares of our common stock in the public market could occur in the future.
result in a dilution of your voting power and an increase in the number of shares of common stock eligible for future resale in
the public market, which may negatively impact the trading price of our shares of common stock.The
are exercised (including with respect to the warrants and any Series B Preferred issued in this offering), additional shares of
of a substantial number of shares of our common stock in the public market or otherwise following this offering, or the
perception that such sales could occur, could adversely affect the market price of our common stock.
2017, each after giving effect to the receipt of the net proceeds from our sale in this offering of shares of common stock at
public offering price per share of common stock$0.39Historical
warrants to be issued in this offering, (v) shares of our common stock issuable by the Company upon exercise of the underwriter’s
warrants to be issued in this offering, (v) shares of our common stock issuable by the Company upon exercise of the underwriter’s
number of shares of our common stock outstanding after this offering will fluctuate depending on how many Class B Units are sold
number of shares of our common stock outstanding after this offering will fluctuate depending on how many Class B Units are sold
number of shares of our common stock outstanding after this offering will fluctuate depending on how many Class B Units are sold
clinical effectiveness of the products.Professional service costs declined 77% during the year ended
safety initiatives.Akers believes that low-cost, unit-use testing not only saves time
safety initiatives.Akers believes that low-cost, unit-use testing not only saves time